HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract researchHYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research

Sai Life Sciences to Recruit 700+ Professionals in FY27

2026/02/20 17:15
Okuma süresi: 3 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen crypto.news@mexc.com üzerinden bizimle iletişime geçin.

HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services.

The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing, among others.

A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally, reflecting the increasing complexity of programs being entrusted to Sai Life Sciences and the higher scientific expectations placed on Indian CRDMOs by global innovator companies.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “We are at an inflection point for the Indian CRDMO industry. Global supply-chain rebalancing, the need for resilient development and manufacturing partners, and the rising sophistication of outsourced science are converging in India’s favour. Demand for high-quality, integrated partners is already visible, and this expansion is about preparing ourselves to serve that demand at scale — with the right infrastructure, strong digital and quality systems, and deep scientific capability.”

Krishna added, “For scientists, this is a genuinely exciting moment. They have the opportunity to work on globally relevant, high-impact programs while being based in India. We believe this phase of growth creates a compelling opportunity for Indian scientists anywhere in the world to consider building the next chapter of their careers here—without compromising on scientific rigor, exposure, or the quality of work.”

The new roles will support growing activity in areas such as complex small-molecule synthesis, high-throughput experimentation, data-enabled drug discovery, and late-stage CMC and commercial manufacturing scale-up.

As part of its talent strategy, Sai Life Sciences has launched a global alumni engagement platform and is strengthening learning, leadership development, and internal mobility programs to support long-term career growth.

Sai Life Sciences operates across India, the UK, and the US, serving global pharmaceutical and biotechnology companies. Its Manchester site focuses on process R&D, while its Boston Biology facility supports early discovery collaborations and client engagement. The majority of new roles will be based in Hyderabad, home to the company’s largest integrated R&D campus. With more than 3,400 scientists and professionals currently on board, the planned hiring reflects its continued growth and its expanding role as a global CRDMO partner.

About Sai Life Sciences

Sai Life Sciences is a full-service CRDMO working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules. With operations across India, the UK, and the US, Sai Life Sciences offers scientific expertise, world-class infrastructure, and a culture of excellence focused on quality, safety, and sustainability. www.sailife.com

Contacts

For further information, contact:

Sriram Gopalakrishnan
Vice President, Corporate Communications
Sai Life Sciences  
Ph: +91 9121295355
sriram.g@sailife.com

Piyasa Fırsatı
Sharpe AI Logosu
Sharpe AI Fiyatı(SAI)
$0.0009237
$0.0009237$0.0009237
-1.73%
USD
Sharpe AI (SAI) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen crypto.news@mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Why LYNO’s Presale Could Trigger the Next Wave of Crypto FOMO After SOL and PEPE

Why LYNO’s Presale Could Trigger the Next Wave of Crypto FOMO After SOL and PEPE

The post Why LYNO’s Presale Could Trigger the Next Wave of Crypto FOMO After SOL and PEPE appeared on BitcoinEthereumNews.com. Cryptocirca has never been bereft of hype cycles and fear of missing out (FOMO). The case of Solana (SOL) and Pepe (PEPE) is one of the brightest examples that early investments into the correct projects may yield the returns that are drifting. Today there is an emerging rival in the limelight—LYNO. LYNO is in its presale stage, and already it is being compared to former breakout tokens, as many investors are speculating that LYNO will be the next big thing to ignite the market in a similar manner. Early Bird Presale: Lowest Price LYNO is in the Early Bird presale and costs only $0.050 for each token; the initial round will rise to $0.055. To date, approximately 629,165.744 tokens have been sold, with approximately $31,458.287 of that amount going towards the $100,000 project goal.  The crypto presales allow investors the privilege to acquire tokens at reduced prices before they become available to the general market, and they tend to bring substantial returns in the case of great fundamentals. The final goal of the project: 0.100 per token. This gradual development underscores increasing investor confidence and it brings a sense of urgency to those who wish to be first movers. LYNO’s Edge in a Competitive Market LYNO isn’t just another presale token—it’s a powerful AI-driven cross-chain arbitrage platform designed to deliver real utility and long-term growth. Operating across 15+ blockchains, LYNO’s AI engine analyzes token prices, liquidity, volume, and gas fees in real-time to identify the most profitable trade routes. It integrates with bridges like LayerZero, Wormhole, and Axelar, allowing assets to move instantly across networks, so no opportunity is missed.  The platform also includes community governance, letting $LYNO holders vote on protocol upgrades and fee structures, staking rewards for long-term investors, buyback-and-burn mechanisms to support token value, and audited smart…
Paylaş
BitcoinEthereumNews2025/09/18 16:11
The $55 Oil Trade Is Still on the Table, but Brent’s Chart Has Conditions

The $55 Oil Trade Is Still on the Table, but Brent’s Chart Has Conditions

The post The $55 Oil Trade Is Still on the Table, but Brent’s Chart Has Conditions appeared on BitcoinEthereumNews.com. The oil price surged on April 2 as Brent
Paylaş
BitcoinEthereumNews2026/04/02 18:30
Covéa Chooses Shift Technology as Strategic Partner for Fraud and Risk Management

Covéa Chooses Shift Technology as Strategic Partner for Fraud and Risk Management

Covéa has selected Shift Technology as a long-term partner to support a consistent and shared view of risk from policy inception through to claims settlement The
Paylaş
ffnews2026/04/02 07:00

Trade GOLD, Share 1,000,000 USDT

Trade GOLD, Share 1,000,000 USDTTrade GOLD, Share 1,000,000 USDT

0 fees, up to 1,000x leverage, deep liquidity